Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia (ASPIRE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier:
NCT00706654
First received: June 25, 2008
Last updated: July 12, 2013
Last verified: July 2013
  Purpose

The purpose of the this trial is to evaluate the efficacy, safety, and tolerability of an intramuscular (IM) depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia

The trial is designed into three treatment phases. Phase 1 is designed to allow for a subject to be converted from the current anti-psychotic treatment to oral non-generic aripiprazole monotherapy (oral conversion phase from 4 to 6 weeks). During Phase 2 the subject will be stabilized on oral non-generic aripiprazole monotherapy. Once the subject is stabilized in Phase 2 (oral stabilization phase from minimum 8 weeks to maximum 28 weeks), they are eligible to be randomized into the double-blind IM depot maintenance phase, Phase 3. During Phase 3, the subject will be assessed for exacerbation of psychotic symptoms and impending relapse for up to 38 weeks.


Condition Intervention Phase
Schizophrenia
Drug: Aripiprazole depot 300 or 400 mg
Drug: Aripiprazole 10-30 mg orally
Drug: Aripiprazole depot 25 or 50 mg
Drug: Placebo depot
Drug: Placebo tablets
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Schizophrenia

Resource links provided by NLM:


Further study details as provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:

Primary Outcome Measures:
  • Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria by the End of Week 26 [ Time Frame: Baseline to Week 26 ] [ Designated as safety issue: No ]
    A patient had exacerbation of psychotic symptoms/impending relapse if they met any of the following 4 criteria. 1) Clinical Global Impression of Improvement score ≥ 5 and either an increase on any of the following Positive and Negative Syndrome Scale (PANSS) items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score > 4 with an increase of ≥ 2 on that item since randomization or an increase on any of the same PANSS items to a score > 4 and an increase of ≥ 4 on the same combined PANSS items since randomization, 2) Hospitalization due to worsening of psychotic symptoms, 3) Clinical Global Impression of Severity of Suicide (CGI-SS) score of 4 or 5 on Part 1 and/or 6 or 7 on Part 2, or 4) Violent behavior resulting in clinically significant self-injury, injury to another person, or property damage.


Secondary Outcome Measures:
  • Time to Exacerbation of Psychotic Symptoms/Impending Relapse [ Time Frame: Baseline to the end of the study (Week 38) ] [ Designated as safety issue: No ]
  • Percentage of Responders up to Week 38 [ Time Frame: Baseline to the end of the study (Week 38) ] [ Designated as safety issue: No ]
    A patient was considered to be a responder if all of the following criteria were met. 1) Outpatient status, 2) PANSS total score ≤ 80, 3) Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): Conceptual disorganization, suspiciousness, hallucinatory behavior, unusual thought content, and 4) Clinical Global Impression of Severity of Illness (CGI-S) ≤ 4 (moderately ill) and 5) CGI-SS ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2.

  • Percentage of Patients Achieving Remission [ Time Frame: Baseline to the end of the study (Week 38) ] [ Designated as safety issue: No ]
    A patient was considered to have achieved remission if they had a score of ≤ 3 on each of the following PANSS items, maintained for a period of 6 months: Delusions (P1), unusual thought content (G9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted affect (N1), social withdrawal (N4), and lack of spontaneity (N6).


Enrollment: 937
Study Start Date: September 2008
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Aripiprazole depot 300 or 400 mg
Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 38 weeks.
Drug: Aripiprazole depot 300 or 400 mg
Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
Other Name: Abilify
Drug: Placebo tablets
Placebo tablets were identical in appearance to the aripiprazole tablets.
Active Comparator: Aripiprazole 10-30 mg orally
Patients received aripiprazole 10-30 mg orally daily for 38 weeks.
Drug: Aripiprazole 10-30 mg orally
Aripiprazole was supplied as 10, 15, and 20 mg tablets. The dose that the patient received was based on the investigator's judgment and the subject's clinical need.
Other Name: Abilify
Drug: Placebo depot
Placebo depot was supplied in lyophilized vials.
Experimental: Aripiprazole depot 25 or 50 mg
Patients received aripiprazole 25 mg or 50 mg depot intramuscularly every 28 days for 38 weeks.
Drug: Aripiprazole depot 25 or 50 mg
Aripiprazole depot was supplied in 200 mg lyophilized vials. Patients received aripiprazole 25 mg if they were unable to tolerate aripiprazole 50 mg.
Other Name: Abilify
Drug: Placebo tablets
Placebo tablets were identical in appearance to the aripiprazole tablets.

Detailed Description:

This will be a randomized, double-blind, active-controlled study consisting of a screening phase and 3 treatment phases. Eligibility will be determined during a screening phase of 2 to 42 days. Subjects currently receiving oral treatment with an anti-psychotic other than non-generic aripiprazole will enter Phase 1, and subjects with a lapse in aripiprazole or other anti-psychotic treatment at the time of study entry ("lapse" defined as > 3 consecutive days without medication) will enter directly into Phase 2.

During Phase 1 (oral conversion), subjects will be cross-titrated during weekly visits from other anti-psychotics to oral non-generic aripiprazole monotherapy over a minimum of 4 weeks and a maximum of 6 weeks. During Phase 2 (that will be a minimum of 8 weeks and a maximum of 28 weeks in duration), subjects will be assessed bi-weekly and stabilized on an oral dose of aripiprazole ranging from 10 mg to 30 mg daily. After stability criteria are met at Phase 2, subjects are eligible to be randomized into the double-blind IM depot maintenance phase, Phase 3. Subjects will be randomized with a 2:2:1 (aripiprazole IM depot 300-400 mg monthly, oral aripiprazole 10-30 mg daily, aripiprazole IM depot 25-50 mg monthly). During Phase 3 subjects will be assessed for impending relapse/exacerbation of psychotic symptoms. If a subject is identified with impending relapse/exacerbation of psychotic symptoms, they will be withdrawn from the trial and given the opportunity to enroll into an open-label aripiprazole IM depot trial, 31-08-248 (NCT00731549). Alternatively, any subject that discontinues in Phase 3 (up to and including Week 38) will have the option to enroll into an open-label aripiprazole IM depot trial, 31-08-248 (NCT00731549).

The enrollment figure includes re-screened patients.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects who are able to provide written informed consent and/or consent obtained from a legally acceptable representative (as required by Institutional Review Board/Independent Ethics Committee [IRB/IEC]), prior to the initiation of any protocol-required procedures.
  • Male and female subjects 18 to 60 years of age, inclusive, at time of informed consent.
  • Subjects with a current diagnosis of schizophrenia as defined by Diagnostic and Statistical Manual of Mental Disorders, version 4, Text Revision (DSM-IV-TR) criteria and a history of the illness for at least 3 years prior to screening.
  • Subjects who, in the investigator's judgment, require chronic treatment with an anti-psychotic medication.
  • Subjects able to understand the nature of the study and follow protocol requirements, including the prescribed dosage regimens, tablet ingestion, IM depot injection, discontinuation of prohibited concomitant medications, who can read and understand the written word in order to complete patient-reported outcome measures, and who can be reliably rated on assessment scales.

Exclusion Criteria:

  • Subjects with a current DSM-IV-TR diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic, or other cognitive disorders. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
  • Subjects with schizophrenia that are considered resistant/refractory to antipsychotic treatment by history or response only to clozapine.
  • Subjects with a significant risk of violent behavior or a significant risk of committing suicide based on history or investigator's judgment.
  • Subjects who currently meet DSM-IV-TR criteria for substance dependence; including alcohol and benzodiazepines, but excluding caffeine and nicotine, or 2 positive drug screens for cocaine.
  • Subjects who are known to be allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones, or hypersensitivity to anti-psychotic agents, including aripiprazole.
  • Subjects with a history of neuroleptic malignant syndrome or clinically significant tardive dyskinesia at screening.
  • Subjects with uncontrolled thyroid function abnormalities.
  • Subjects with a history of seizures, neuroleptic malignant syndrome, clinically significant tardive dyskinesia, or other medical condition that would expose the subject to undue risk or interfere with study assessments.
  • Subjects who are involuntarily incarcerated.
  • Subjects who have undergone electroconvulsive therapy within 180 days of entry into Phase 2.
  • Subjects who have used an investigational agent within 30 days of screening; and prior participation in a clinical study with aripiprazole IM depot.
  • Subjects with clinically significant abnormalities in laboratory test results, vital signs, or ECG results.
  • Subjects hospitalized for more than 30 days in the 90 days prior to Phase 1 (or Phase 2 for subjects bypassing Phase 1).
  • Subjects requiring more than 1 benzodiazepine beyond screening (eg, lorazepam and oxazepam).
  • Subjects who fail to wash-out from prohibited concomitant medications, including the use of CYP2D6 or CYP3A4 inhibitors or CYP3A4 inducers, antipsychotics, antidepressants (including monoamine oxidase inhibitors [MAOI]), and mood stabilizers, during screening and Phase 1.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00706654

  Hide Study Locations
Locations
United States, California
Cerritos, California, United States, 90703
Escondido, California, United States, 92025
Garden Grove, California, United States, 92845
Oceanside, California, United States, 92056
Orange, California, United States, 92868-3298
Orange, California, United States, 92868
Pasadena, California, United States, 91106
Pico Rivera, California, United States, 90660
San Diego, California, United States, 92102
San Diego, California, United States, 92123
San Diego, California, United States, 92103-8620
Torrance, California, United States, 90502
United States, District of Columbia
Washington, District of Columbia, United States, 20016
United States, Florida
Gainesville, Florida, United States, 32608
Kissimmee, Florida, United States, 34741
Plantation, Florida, United States, 33317
Tampa, Florida, United States, 33613
United States, Illinois
Chicago, Illinois, United States, 60612
Oak Brook, Illinois, United States, 60523
United States, Louisiana
Shreveport, Louisiana, United States, 71104
United States, Maryland
Towson, Maryland, United States, 21286
United States, Missouri
Kansas City, Missouri, United States, 64108
United States, New York
Buffalo, New York, United States, 14213
New York, New York, United States, 10003
New York, New York, United States, 10035
Rochester, New York, United States, 14624
United States, North Carolina
Hickory, North Carolina, United States, 28601
South Carolina, North Carolina, United States, 29425
United States, Ohio
Garfield Heights, Ohio, United States, 44125
Toledo, Ohio, United States, 43609
United States, Oklahoma
Oklahoma City, Oklahoma, United States, 73112
United States, South Carolina
Charleston, South Carolina, United States, 29401
Charleston, South Carolina, United States, 29407
United States, Tennessee
Johnson City, Tennessee, United States, 37614-1707
Nashville, Tennessee, United States, 37212
United States, Texas
Arlington, Texas, United States, 76011
Austin, Texas, United States, 78756
United States, Virginia
Richmond, Virginia, United States, 23230
United States, Wisconsin
Milwaukee, Wisconsin, United States, 53226
Austria
Innsbruck, Austria, A-6020
Belgium
Brugge, Belgium, 8200
Bulgaria
Bourgas, Bulgaria, 8000
Pazardjik, Bulgaria, 4400
Pleven, Bulgaria, 5800
Plovdiv, Bulgaria, 4000
Sofia, Bulgaria, 1113
Sofia, Bulgaria, 1431
Sofia, Bulgaria, 1632
Varna, Bulgaria, 9000
Chile
Santiago, Chile, 7500710
Santiago, Chile, 8053095
Santiago, Chile, 7510186
Santiago, Chile, 8900085
Santiago, Chile, 8330838
Santiago, Chile, 7510041
Temuco, Chile, 4781151
Valdivia, Chile, 5090145
Croatia
Zagreb, Croatia, 10 090
Zagreb, Croatia, 10000
Estonia
Jamejala, Viljandi County, Estonia, 71024
Meegomäe, Estonia, 65526
Tallinn, Estonia, 13419
Tallinn, Estonia, 10613
Tartu, Estonia, 50406
Tartu, Estonia, 50417
France
Bully Les Mines, France, 62160
Elancourt, France, 78990
Rennes, France, 35703
Saint Nazaire, France, 44606
Hungary
Baja, Hungary, 6500
Balassagyarmat, Hungary, 2660
Cegléd, Hungary, 2700
Győőor, Hungary, 9024
Italy
Milano, Italy, 20157
Milano, Italy, 20142
Pisa, Italy, 56126
Korea, Republic of
Busan, Korea, Republic of, 614-735
Daejeon, Korea, Republic of, 301-721
Gwangju, Korea, Republic of, 501-757
Incheon, Korea, Republic of, 400-711
Seoul, Korea, Republic of, 150-950
Seoul, Korea, Republic of, 137-701
Seoul, Korea, Republic of, 110-744
Poland
Belchatow, Poland, 97-400
Bialystok, Poland, 15-879
Bydgoszcz, Poland, 85-096
Choroszcz, Poland, 16-070
Krakow, Poland, 31-501
Leszno, Poland, 64-100
Pruszków, Poland, 05-802
Sosnowiec, Poland, 41-200
Wroclaw, Poland, 50-227
Puerto Rico
San Juan, Puerto Rico, 00918
South Africa
Pretoria, Gauteng, South Africa, 0001
Cape Town, Western Province, South Africa, 7530
Thailand
Muang, Chiangmai, Thailand, 50100
Muang, Chiangmai, Thailand, 50200
Bangkok, Thailand, 10330
Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
Investigators
Study Director: Raymond Sanchez, MD Otsuka Pharmaceutical Development & Commercialization, Inc.
  More Information

No publications provided by Otsuka Pharmaceutical Development & Commercialization, Inc.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier: NCT00706654     History of Changes
Other Study ID Numbers: 31-07-247
Study First Received: June 25, 2008
Results First Received: March 29, 2013
Last Updated: July 12, 2013
Health Authority: United States: Food and Drug Administration
Austria: Federal Office for Safety in Health Care
Belgium: Federal Agency for Medicinal Products and Health Products
Bulgaria: Ministry of Health
Chile: Instituto de Salud Pública de Chile
Croatia: Ministry of Health and Social Care
Estonia: The State Agency of Medicine
France: Ministry of Health
Hungary: National Institute of Pharmacy
Italy: Ministry of Health
Poland: Ministry of Health
South Africa: Medicines Control Council
South Korea: Korea Food and Drug Administration (KFDA)
Thailand: Food and Drug Administration

Keywords provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:
Aripiprazole
Intramuscular (IM) depot
Schizophrenia

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Aripiprazole
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on October 19, 2014